FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283772009> ?p ?o ?g. }

• W4283772009 endingPage "S352" @default.
• W4283772009 startingPage "S352" @default.
• W4283772009 abstract "The first-line treatment in advanced pancreatic cancer (ACP) is well established by phase III studies, with protocols FOLFIRINOX (FF) and gemcitabine/ nab-paclitaxel (GN). There are no phase III specifying optimal sequencing after disease progression to these first lines. The use of nabpaclitaxel was approved in Brazil for ACP treatment in 2017 and there is no approval for lipossomal irinotecan. This retrospective cohort was held from the database of patients treated with chemotherapy for ACP in Americas Oncologia RJ, from June 2017 to January 2021. The primary endpoint was assessment of treatment sequencing and overall survival (OS). 116 patients were analyzed with a median follow up of 10 months. At diagnosis the average age was 64.6 years, 52.6% were male and around 90% had performance status (PS) 2 - HR 0.30; CI 95% 0.17-0.54; p 2 lines, patients submitted to fewer lines had lower BMI (10.4% had BMI < 18.9 vs 5% ), younger age (62.5% vs 80% younger than 70 years) and worst PS (88% vs 95% PS 0-1). The most common treatment sequencings protocols were: 56% with fluorouracil protocols followed by gemcitabine combo (sequence 1), 28% with gemcitabine combo followed by protocols with fluorouracil (sequence 2) and 16% protocols with fluorouracil followed by gemcitabine alone (sequence 3). The median OS was significant inferior in sequence 3 (HR 4.24; 95% CI 1.52-11.8; p=0.006), with no differences between 1 and 2 sequences, regardless of age, BMI and OS in first line (HR 5.51; CI 95% 1.80-16.9; p = 0.0030). Fourteen pacientes were reexposed to previous lines, previously interrupted by disease progression. The median OS for them was 25 months. The most prescribed protocols were FF ( 70%) and GN (25%). The univariate analysis didn´t find significant predictive factors. There were no statistical differences between sequencing flurorouracil combos with protocols with gemcitabine or GN followed by fluorouracil combos in pacientes treated in our service. The choice of each regimen should be individualized, taken into account mainly patient´s PS, age and BMI." @default.
• W4283772009 created "2022-07-03" @default.
• W4283772009 creator A5030066269 @default.
• W4283772009 creator A5088575702 @default.
• W4283772009 date "2022-06-01" @default.
• W4283772009 modified "2023-09-25" @default.
• W4283772009 title "P-299 Real-world assessment of treatment sequencing of patients with advanced pancreatic cancer in a private practice in Rio de Janeiro, Brazil (Americas Oncologia RJ)" @default.
• W4283772009 doi "https://doi.org/10.1016/j.annonc.2022.04.388" @default.
• W4283772009 hasPublicationYear "2022" @default.
• W4283772009 type Work @default.
• W4283772009 citedByCount "0" @default.
• W4283772009 crossrefType "journal-article" @default.
• W4283772009 hasAuthorship W4283772009A5030066269 @default.
• W4283772009 hasAuthorship W4283772009A5088575702 @default.
• W4283772009 hasBestOaLocation W42837720091 @default.
• W4283772009 hasConcept C121608353 @default.
• W4283772009 hasConcept C126322002 @default.
• W4283772009 hasConcept C141071460 @default.
• W4283772009 hasConcept C143998085 @default.
• W4283772009 hasConcept C203092338 @default.
• W4283772009 hasConcept C2776694085 @default.
• W4283772009 hasConcept C2777148230 @default.
• W4283772009 hasConcept C2780210213 @default.
• W4283772009 hasConcept C2780258809 @default.
• W4283772009 hasConcept C2780259306 @default.
• W4283772009 hasConcept C2780456651 @default.
• W4283772009 hasConcept C526805850 @default.
• W4283772009 hasConcept C535046627 @default.
• W4283772009 hasConcept C71924100 @default.
• W4283772009 hasConcept C72563966 @default.
• W4283772009 hasConcept C90924648 @default.
• W4283772009 hasConceptScore W4283772009C121608353 @default.
• W4283772009 hasConceptScore W4283772009C126322002 @default.
• W4283772009 hasConceptScore W4283772009C141071460 @default.
• W4283772009 hasConceptScore W4283772009C143998085 @default.
• W4283772009 hasConceptScore W4283772009C203092338 @default.
• W4283772009 hasConceptScore W4283772009C2776694085 @default.
• W4283772009 hasConceptScore W4283772009C2777148230 @default.
• W4283772009 hasConceptScore W4283772009C2780210213 @default.
• W4283772009 hasConceptScore W4283772009C2780258809 @default.
• W4283772009 hasConceptScore W4283772009C2780259306 @default.
• W4283772009 hasConceptScore W4283772009C2780456651 @default.
• W4283772009 hasConceptScore W4283772009C526805850 @default.
• W4283772009 hasConceptScore W4283772009C535046627 @default.
• W4283772009 hasConceptScore W4283772009C71924100 @default.
• W4283772009 hasConceptScore W4283772009C72563966 @default.
• W4283772009 hasConceptScore W4283772009C90924648 @default.
• W4283772009 hasLocation W42837720091 @default.
• W4283772009 hasOpenAccess W4283772009 @default.
• W4283772009 hasPrimaryLocation W42837720091 @default.
• W4283772009 hasRelatedWork W1883975635 @default.
• W4283772009 hasRelatedWork W1974538215 @default.
• W4283772009 hasRelatedWork W2012954058 @default.
• W4283772009 hasRelatedWork W2599910524 @default.
• W4283772009 hasRelatedWork W2910998150 @default.
• W4283772009 hasRelatedWork W3045328550 @default.
• W4283772009 hasRelatedWork W3092133951 @default.
• W4283772009 hasRelatedWork W4310753901 @default.
• W4283772009 hasRelatedWork W4380150473 @default.
• W4283772009 hasRelatedWork W4384071429 @default.
• W4283772009 hasVolume "33" @default.
• W4283772009 isParatext "false" @default.
• W4283772009 isRetracted "false" @default.
• W4283772009 workType "article" @default.